|
1
|
Brahmer JR, Drake CG, Wollner I, Powderly
JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller
TL, et al: Phase I study of single-agent anti-programmed death-1
(MDX-1106) in refractory solid tumors: Safety, clinical activity,
pharmacodynamics, and immunologic correlates. J Clin Oncol.
28:3167–3175. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: KEYNOTE-189 investigators: Pembrolizumab plus
chemotherapy in metastatic non-small-cell lung cancer. N Engl J
Med. 378:2078–2092. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Delaney G, Jacob S, Featherstone C and
Barton M: The role of radiotherapy in cancer treatment: Estimating
optimal utilization from a review of evidence-based clinical
guidelines. Cancer. 104:1129–1137. 2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ringborg U, Bergqvist D, Brorsson B,
Cavallin-Ståhl E, Ceberg J, Einhorn N, Frödin JE, Järhult J,
Lamnevik G, Lindholm C, et al: The swedish council on technology
assessment in health care (SBU) systematic overview of radiotherapy
for cancer including a prospective survey of radiotherapy practice
in Sweden 2001-summary and conclusions. Acta Oncol. 42:357–365.
2003.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Walle T, Martinez Monge R, Cerwenka A,
Ajona D, Melero I and Lecanda F: Radiation effects on antitumor
immune responses: Current perspectives and challenges. Ther Adv Med
Oncol. 10(1758834017742575)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Demaria S, Ng B, Devitt ML, Babb JS,
Kawashima N, Liebes L and Formenti SC: Ionizing radiation
inhibition of distant untreated tumors (abscopal effect) is immune
mediated. Int J Radiat Oncol Biol Phys. 58:862–870. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Trotti A, Colevas AD, Setser A and Basch
E: Patient-reported outcomes and the evolution of adverse event
reporting in oncology. J Clin Oncol. 25:5121–5127. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Colton M, Cheadle EJ, Honeychurch J and
Illidge TM: Reprogramming the tumour microenvironment by
radiotherapy: Implications for radiotherapy and immunotherapy
combinations. Radiat Oncol. 15(254)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dovedi SJ, Cheadle EJ, Popple AL, Poon E,
Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO,
et al: Fractionated radiation therapy stimulates antitumor immunity
mediated by both resident and infiltrating polyclonal T-cell
populations when combined with PD-1 blockade. Clin Cancer Res.
23:5514–5526. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Deng L, Liang H, Burnette B, Beckett M,
Darga T, Weichselbaum RR and Fu YX: Irradiation and anti-PD-L1
treatment synergistically promote antitumor immunity in mice. J
Clin Invest. 124:687–695. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Twyman-Saint Victor C, Rech AJ, Maity A,
Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi
PM, et al: Radiation and dual checkpoint blockade activate
non-redundant immune mechanisms in cancer. Nature. 520:373–377.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shaverdian N, Lisberg AE, Bornazyan K,
Veruttipong D, Goldman JW, Formenti SC, Garon EB and Lee P:
Previous radiotherapy and the clinical activity and toxicity of
pembrolizumab in the treatment of non-small-cell lung cancer: A
secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol.
18:895–903. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Samstein R, Rimner A, Barker CA and Yamada
Y: Combined immune checkpoint blockade and radiation therapy:
timing and dose fractionation associated with greatest survival
duration among over 750 treated patients. Int J Radiat Oncol Biol
Phys. 99 (Suppl 2):S129–S130. 2017.
|
|
16
|
Masini C, Iotti C, De Giorgi U, Bellia RS,
Buti S, Salaroli F, Zampiva I, Mazzarotto R, Mucciarini C,
Baldessari C, et al: Nivolumab (NIVO) in combination with
stereotactic body radiotherapy (SBRT) in pretreated patients (pts)
with metastatic renal cell carcinoma (mRCC): First results of phase
II NIVES study. J Clin Oncol. 38 (6 Suppl)(S613)2020.
|
|
17
|
Hammers HJ, Vonmerveldt D, Ahn C, Nadal
RM, Drake CG, Folkert MR, Lain AM, Courtney KD, Brugarolas J, Song
DY, et al: Combination of dual immune checkpoint inhibition (ICI)
with stereotactic radiation (SBRT) in metastatic renal cell
carcinoma (mRCC) (RADVAX RCC). J Clin Oncol. 38 (Suppl 6):614.
2020.
|
|
18
|
Deutsch E, Chargari C, Galluzzi L and
Kroemer G: Optimising efficacy and reducing toxicity of anticancer
radioimmunotherapy. Lancet Oncol. 20:e452–e463. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jagodinsky JC, Harari PM and Morris ZS:
The promise of combining radiation therapy with immunotherapy. Int
J Radiat Oncol Biol Phys. 108:6–16. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Von Reibnitz D, Chaft JE, Wu AJ, Samstein
R, Hellmann MD, Plodkowski AJ, Zhang Z, Shi W, Dick-Godfrey R,
Panchoo KH, et al: Safety of combining thoracic radiation therapy
with concurrent versus sequential immune checkpoint inhibition. Adv
Radiat Oncol. 3:391–398. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Peters S, Felip E, Dafni U, Belka C,
Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, et
al: Safety evaluation of nivolumab added concurrently to
radiotherapy in a standard first line chemo-radiotherapy regimen in
stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung
Cancer. 133:83–87. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Chajon E, Castelli J, Marsiglia H and De
Crevoisier R: The synergistic effect of radiotherapy and
immunotherapy: A promising but not simple partnership. Crit Rev
Oncol Hematol. 111:124–132. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Camphausen K, Moses MA, Ménard C, Sproull
M, Beecken WD, Folkman J and O'Reilly MS: Radiation abscopal
antitumor effect is mediated through p53. Cancer Res. 63:1990–1993.
2003.PubMed/NCBI
|
|
24
|
Amin NP, Zainib M, Parker SM, Agarwal M
and Mattes MD: Multicenter report on toxicities of concurrent
nivolumab and radiation therapy. Adv Radiat Oncol. 3:399–404.
2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Bang A, Wilhite TJ, Pike LRG, Cagney DN,
Aizer AA, Taylor A, Spektor A, Krishnan M, Ott PA, Balboni TA, et
al: Multicenter evaluation of the tolerability of combined
treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and
palliative radiation therapy. Int J Radiat Oncol Biol Phys.
98:344–351. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Dromain C, Beigelman C, Pozzessere C,
Duran R and Digklia A: Imaging of tumour response to immunotherapy.
Eur Radiol Exp. 4(2)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Ge X, Zhang Z, Zhang S, Yuan F, Zhang F,
Yan X, Han X, Ma J, Wang L, Tao H, et al: Immunotherapy beyond
progression in patients with advanced non-small cell lung cancer.
Transl Lung Cancer Res. 9:2391–2400. 2020.PubMed/NCBI View Article : Google Scholar
|
